MarketCapExport financials
Organogenesis Holdings (ORGO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Organogenesis Holdings Balance Sheet 2025-2011 | ORGO
Brief overview of Organogenesis Holdings 's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets added +35.1%, reaching $598.7 million from $443.3 million five periods earlier; annual growth near 7.8% remained solid.
Liabilities increased less than assets, posting -18.4% versus +35.1%. That relationship usually strengthens the balance sheet.
Internal capital represents 50.1% of the balance sheet, previously 54.4%. This is a strong capital position.
The period ended with net cash: net debt stood at -$75.9 million. This supports financial flexibility.
Cash accounts for 15.6% of assets versus 25.8% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$3.1 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
The indicators point to a strong balance sheet position for Organogenesis Holdings : funding is balanced and liability risks appear controlled.
Annual Balance Sheet Organogenesis Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-75.9 M | -131 M | -32.5 M | -22.5 M | -28.1 M | -14.4 M | 40.4 M | 20.3 M | 49.8 M | -1.04 M | 48.9 K | - | - | - | - |
Long Term Debt |
12.8 M | 718 K | 66.6 M | 71.2 M | 74.1 M | 70 M | 83.1 M | 39.1 M | 52.1 M | - | - | - | - | - | - |
Long Term Debt Current |
4.95 M | 4.27 M | 4.73 M | 8.71 M | 11.8 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
64.7 M | 35.1 M | 101 M | 109 M | 119 M | 80.2 M | 105 M | 50.2 M | 10.8 M | 10.8 M | - | - | - | - | - |
Total Current Liabilities |
100 M | 77.5 M | 80.5 M | 75 M | 82.7 M | 68.2 M | 59.9 M | 66.4 M | 52 M | 478 K | - | - | - | - | - |
Total Liabilities |
165 M | 113 M | 181 M | 184 M | 202 M | 148 M | 165 M | 117 M | 157 M | 11.3 M | 416 K | - | - | - | - |
Retained Earnings |
-3.08 M | -40.1 M | -41 M | -45.3 M | -60.8 M | -155 M | -171 M | -130 M | -65.4 M | -234 K | -25.2 K | - | - | - | - |
Total Assets |
599 M | 498 M | 460 M | 449 M | 443 M | 290 M | 221 M | 164 M | 149 M | 311 M | 416 K | - | - | - | - |
Cash and Cash Equivalents |
93.7 M | 136 M | 104 M | 102 M | 114 M | 84.4 M | 60.2 M | 21.3 M | 2.31 M | 1.04 M | 126 K | - | - | - | - |
Book Value |
434 M | 385 M | 279 M | 266 M | 241 M | 142 M | 55.6 M | 47 M | -8.56 M | 300 M | -162 | - | - | - | - |
Total Shareholders Equity |
300 M | 263 M | 279 M | 266 M | 241 M | 142 M | 55.6 M | 47 M | -15.3 M | -16 M | -162 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Organogenesis Holdings
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
20.4 M | 21.1 M | 21.8 M | 22.5 M | 23.5 M | 24.6 M | 25.6 M | 25.2 M | 22.8 M | 23.5 M | 24.4 M | 25.1 M | 38.8 M | 40.5 M | 40.3 M | 20.9 M | 43 M | 43.7 M | 45.3 M | 46.9 M | 24.2 M | 24.2 M | 11 M | 70 M | 99.4 M | 99.4 M | 93.5 M | 49.6 M | 50 M | 40 M | 40 M | - | - | - | - | 52.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
58.5 M | 61.4 M | 62.6 M | 64.7 M | 33.5 M | 34.1 M | 34.3 M | 35.1 M | 90.5 M | 93.9 M | 97.7 M | 101 M | 104 M | 106 M | 106 M | 109 M | 112 M | 114 M | 116 M | 119 M | 100 M | 92.1 M | 87.9 M | 80.2 M | 115 M | 115 M | 113 M | 105 M | 105 M | 94.5 M | 91.6 M | 60.5 M | 5.13 M | 10.8 M | 10.8 M | 105 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
106 M | 118 M | 139 M | 165 M | 124 M | 99.9 M | 99.3 M | 113 M | 168 M | 180 M | 180 M | 181 M | 186 M | 179 M | 182 M | 184 M | 201 M | 202 M | 195 M | 202 M | 181 M | 177 M | 162 M | 148 M | 181 M | 181 M | 168 M | 165 M | 162 M | 145 M | 144 M | 117 M | 13.1 M | 16.7 M | 15.9 M | 157 M | 13.5 M | 10.9 M | 11 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 416 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-182 M | -153 M | -56.2 M | -3.08 M | -46.8 M | -68.3 M | -59 M | -40.1 M | -47.8 M | -60.1 M | -43.1 M | -41 M | -40.4 M | -43.6 M | -48.9 M | -45.3 M | -52.8 M | -53 M | -61.7 M | -60.8 M | -112 M | -120 M | -141 M | -155 M | -172 M | -192 M | -187 M | -171 M | -167 M | -155 M | -146 M | -130 M | 2.83 M | -2.11 M | -2.46 M | -65.4 M | -1.83 M | 287 K | -93 K | -234 K | -55.7 K | -234 K | -234 K | -25.2 K | -25.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
369 M | 406 M | 520 M | 599 M | 510 M | 461 M | 467 M | 498 M | 446 M | 443 M | 458 M | 460 M | 463 M | 450 M | 446 M | 449 M | 457 M | 456 M | 436 M | 443 M | 370 M | 356 M | 319 M | 290 M | 246 M | 216 M | 208 M | 221 M | 175 M | 168 M | 176 M | 164 M | 316 M | 315 M | 314 M | 149 M | 312 M | 312 M | 311 M | 311 M | 822 K | 311 M | 311 M | 416 K | 416 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
26.9 M | 46.8 M | 92.1 M | 94.3 M | 64.4 M | 73.7 M | 111 M | 136 M | 94.9 M | 90.5 M | 89.3 M | 104 M | 98.8 M | 89.5 M | 89.4 M | 103 M | 108 M | 113 M | 109 M | 115 M | 103 M | 90.3 M | 78 M | 84.8 M | 36.9 M | 40.8 M | 47.1 M | 60.4 M | 23.2 M | 20.2 M | 30.7 M | 21.4 M | 25.9 M | 1.31 M | 918 K | 2.36 M | 118 K | 286 K | 486 K | 1.86 M | 172 K | 1.04 M | 1.04 M | 126 K | 126 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
263 M | 288 M | 381 M | 434 M | 386 M | 361 M | 368 M | 385 M | 279 M | 264 M | 278 M | 279 M | 277 M | 271 M | 264 M | 266 M | 256 M | 254 M | 242 M | 241 M | 189 M | 179 M | 157 M | 142 M | 65.5 M | 35.8 M | 40.3 M | 55.6 M | 12.8 M | 23.2 M | 32.6 M | 47 M | 303 M | 298 M | 298 M | -8.56 M | 299 M | 301 M | 300 M | 300 M | -10.5 M | 300 M | 300 M | -162 | 416 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
120 M | 148 M | 245 M | 300 M | 255 M | 233 M | 243 M | 263 M | 279 M | 264 M | 278 M | 279 M | 277 M | 271 M | 264 M | 266 M | 256 M | 254 M | 242 M | 241 M | 189 M | 175 M | 153 M | 142 M | 61.4 M | 31.8 M | 40.3 M | 55.6 M | 12.8 M | 23.2 M | 32.6 M | 47 M | -24.2 M | -57.2 M | -37.4 M | -15.3 M | 5 M | 5 M | 5 M | -16 M | -30.7 K | 5 M | 5 M | 3.51 M | -162 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Organogenesis Holdings , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
France
Canada
China
Irlanda
Schweden
